Insider trading

Period: 120 months Stock: TCMD + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

317 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

317 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

317 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

317 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
317 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
317 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

317 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
10 Aug 2026
Dodd Sheri Louise Chief Executive Officer
Sold at will
$323.24K 10,978 at 29.44
4.5%
Not planned
11 May 2026
Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER
Sold at will
$113.40K 4,631 at 24.49
3.4%
Not planned
24 Feb 2026
Dodd Sheri Louise Chief Executive Officer
Sold at will
$318.14K 10,993 at 28.94
4.3%
Not planned
24 Feb 2026
Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER
Sold at will
$222.88K 7,701 at 28.94
5.4%
Not planned
24 Feb 2026
Burns Kristie Sr. VP Mktg & Clinical Affairs
Sold at will
$180.76K 6,246 at 28.94
7.0%
Not planned
23 Feb 2026
Dodd Sheri Louise Chief Executive Officer
Sold at will 2×
$431.25K 15,240 at 28.30
5.6%
Not planned
23 Feb 2026
Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER
Sold at will 2×
$156.14K 5,518 at 28.30
3.7%
Not planned
23 Feb 2026
Burns Kristie Sr. VP Mktg & Clinical Affairs
Sold at will 2×
$125.61K 4,439 at 28.30
4.8%
Not planned
2 Jan 2026
Burns Kristie Sr. VP Mktg & Clinical Affairs
Sold on a plan
$148.26K 5,139 at 28.85
6.6%
Planned (10b5-1)
8 Aug 2025
Dodd Sheri Louise Chief Executive Officer
Sold at will
$95.91K 7,762 at 12.36
4.3%
Not planned
12 May 2025
Birkemeyer Elaine M. Chief Financial Officer
Sold on a plan
$29.04K 2,921 at 9.94
2.9%
Planned (10b5-1)
8 May 2025
BURKE WILLIAM W Director
Sold on a plan
$31.91K 3,300 at 9.67
6.4%
Planned (10b5-1)
8 May 2025
Dodd Sheri Louise Chief Executive Officer
Sold at will
$30.95K 3,149 at 9.83
1.7%
Not planned
25 Feb 2025
Sold on a plan
$401.85K 28,338 at 14.18
11.7%
Planned (10b5-1)
25 Feb 2025
Burns Kristie Sr. VP Mktg & Clinical Affairs
Sold at will
$93.16K 6,468 at 14.40
7.7%
Not planned
25 Feb 2025
Birkemeyer Elaine M. Chief Financial Officer
Sold on a plan
$29.98K 2,066 at 14.51
2.0%
Planned (10b5-1)
24 Feb 2025
Sold on a plan
$159.15K 10,938 at 14.55
4.3%
Planned (10b5-1)
24 Feb 2025
Burns Kristie Sr. VP Mktg & Clinical Affairs
Sold at will
$70.75K 4,830 at 14.65
5.4%
Not planned
24 Feb 2025
Birkemeyer Elaine M. Chief Financial Officer
Sold on a plan
$55.54K 3,778 at 14.70
3.5%
Planned (10b5-1)
12 Aug 2024
Ferstler Sherri Lee Senior VP, Sales
Sold at will
$20.26K 1,550 at 13.07
3.8%
Not planned
16 May 2024
Birkemeyer Elaine M. Chief Financial Officer
Sold at will
$41.59K 3,041 at 13.68
4.7%
Not planned
8 May 2024
BURKE WILLIAM W Director
Sold on a plan
$35.15K 2,500 at 14.06
9.0%
Planned (10b5-1)
6 May 2024
Burns Kristie Sr. VP Mktg & Clinical Affairs
Sold at will
$11.71K 815 at 14.37
1.3%
Not planned
29 Feb 2024
REUVERS DANIEL L. President and CEO
Sold on a plan
$21.29K 1,396 at 15.25
0.6%
Planned (10b5-1)
29 Feb 2024
Burns Kristie Sr. VP Mktg & Clinical Affairs
Sold on a plan
$3.71K 243 at 15.25
0.4%
Planned (10b5-1)
27 Feb 2024
REUVERS DANIEL L. President and CEO
Sold on a plan
$73.15K 4,689 at 15.60
1.9%
Planned (10b5-1)
27 Feb 2024
Burns Kristie Sr. VP Mktg & Clinical Affairs
Sold on a plan
$17.00K 1,091 at 15.58
1.7%
Planned (10b5-1)
26 Feb 2024
REUVERS DANIEL L. President and CEO
Sold on a plan
$98.64K 6,239 at 15.81
2.5%
Planned (10b5-1)
26 Feb 2024
Burns Kristie Sr. VP Mktg & Clinical Affairs
Sold on a plan
$32.05K 2,015 at 15.91
3.1%
Planned (10b5-1)
23 Feb 2024
REUVERS DANIEL L. President and CEO
Sold on a plan
$79.85K 5,378 at 14.85
2.7%
Planned (10b5-1)
23 Feb 2024
Burns Kristie Sr. VP Mktg & Clinical Affairs
Sold on a plan
$33.28K 2,249 at 14.80
4.0%
Planned (10b5-1)
7 Aug 2023
REUVERS DANIEL L. President and CEO
Sold at will
$21.81K 1,062 at 20.53
0.8%
Not planned
12 May 2023
BURKE WILLIAM W Director
Sold on a plan
$96.18K 4,400 at 21.86
13.7%
Planned (10b5-1)
8 May 2023
Burns Kristie Sr. VP Mktg & Clinical Affairs
Sold on a plan
$14.66K 786 at 18.65
2.1%
Planned (10b5-1)
8 May 2023
PAULS ERIC Senior VP, Sales
Sold on a plan
$10.20K 550 at 18.55
1.8%
Planned (10b5-1)
1 Mar 2023
Moen Brent Chief Financial Officer
Sold, plan not stated
$19.61K 1,391 at 14.10
2.8%
28 Feb 2023
REUVERS DANIEL L. President and CEO
Sold, plan not stated
$10.19K 700 at 14.56
0.5%
28 Feb 2023
Moen Brent Chief Financial Officer
Sold, plan not stated
$3.66K 251 at 14.58
0.5%
28 Feb 2023
Burns Kristie Sr. VP Mktg & Clinical Affairs
Sold, plan not stated
$1.97K 135 at 14.58
0.4%
28 Feb 2023
PAULS ERIC Senior VP, Sales
Sold, plan not stated
$1.05K 72 at 14.54
0.2%
27 Feb 2023
REUVERS DANIEL L. President and CEO
Sold, plan not stated
$97.53K 6,387 at 15.27
4.8%
27 Feb 2023
Moen Brent Chief Financial Officer
Sold, plan not stated
$58.40K 3,801 at 15.36
7.0%
27 Feb 2023
Burns Kristie Sr. VP Mktg & Clinical Affairs
Sold, plan not stated
$33.28K 2,162 at 15.39
5.5%
27 Feb 2023
PAULS ERIC Senior VP, Sales
Sold, plan not stated
$21.48K 1,401 at 15.33
4.4%
8 Aug 2022
REUVERS DANIEL L. President and CEO
Sold, plan not stated
$9.36K 1,020 at 9.18
1.3%
4 Aug 2022
BURKE WILLIAM W Director
Bought
$44.84K 4,900 at 9.15
25.1%
First buy on file
19 May 2022
BURKE WILLIAM W Director
Sold, plan not stated
$11.13K 1,100 at 10.12
5.3%
6 May 2022
Burns Kristie Sr. VP Mktg & Clinical Affairs
Sold, plan not stated
$13.02K 999 at 13.04
4.4%
6 May 2022
PAULS ERIC Senior VP, Sales
Sold, plan not stated
$7.82K 600 at 13.03
3.2%
7 Mar 2022
Moen Brent Chief Financial Officer
Sold, plan not stated
$3.63K 176 at 20.64
0.3%
Showing 1–50 of 317. Page 1 of 7 Older →